Description
by
Veysel Kayser (Guest Editor)
The book broadly deals with therapeutic monoclonal antibodies (mAbs) and various relevant topics, including different antibody formats such as Antibody-Drug Conjugates (ADC), bispecifics, nanoparticle-based mAbs and HER2+ cancers, immune checkpoint inhibitors and other closely related topics. Each paper was written by leading active research groups in their fields both from academia and industry. The book should be of interest to those scientists and researchers who develop or use biologics, biotherapeutics, biosimilars and biobetters in cancer treatment.
Number of Pages: 298Dimensions: 0.94 x 9.61 x 6.69 INPublication Date: January 25, 2022
Reviews
There are no reviews yet.